Long-Term Prospective Registry in Prostate Cancer Patients From Diverse Urology Practice Settings Following Prolaris® Testing

To evaluate use of the Prolaris score in treatment management decisions in an ethnically

and racially diverse population of men who have been newly diagnosed with prostate cancer

and who are potential candidates for active surveillance. This registry will evaluate

oncologic and co-morbidity outcomes in patients who receive Prolaris testing.

Additionally, the registry will measure the prevalence and distribution of pathogenic

mutations in hereditary cancer risk-associated genes among men with prostate cancer who

meet National Cancer Center Network (NCCN) criteria for hereditary cancer genetic

testing.

The primary objective of this registry is to evaluate initial selection of active

surveillance (Active Surveillance selection) versus definitive therapy (DT) among men

with newly diagnosed prostate cancer who make treatment decisions with Prolaris testing,

and among patient subsets defined by race/ethnicity.

The secondary objectives of the registry are to evaluate progression of from Active

Surveillance to definitive therapy over time and prostate cancer-associated morbidities

that affect quality of life among men with newly diagnosed prostate cancer and who

undergo Prolaris testing, and among patient subsets defined by racial/ethnic background

and ancestry.